IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The employee must remain employed on each vesting date to earn the option over its four-year vesting period.

Rhea-AI Summary

IN8bio (INAB) granted a new employee a stock option covering 60,000 common shares, with a grant date of October 1, 2026.

The Compensation Committee approved the nonqualified option under the 2026 Inducement Plan as an employment inducement under Nasdaq Listing Rule 5635(c)(4). Vesting runs over four years: 25% vests on the first anniversary of the employee’s start date, and the remainder vests in 36 equal monthly installments thereafter. Each vesting date requires continued employment.

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.Option covering 60,000 common shares creates potential dilution if vested and exercised.

Key Figures

Option shares: 60,000 shares Vesting period: 4 years Initial vesting: 25% +1 more

Option shares

60,000 shares

Award to one employee

Vesting period

4 years

Subject to continued employment

Initial vesting

25%

On the employee’s first anniversary

Remaining vesting installments

36 equal monthly installments

After the first-anniversary vesting

Historical Context

1 past event · Latest: Aug 10

1 event

1. Aug 10

   Inducement grant

   24h Move

   +7.6%

   Prior award under the 2026 Inducement Plan covered 4,000 shares with the same four-year vesting schedule.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nonqualified stock option

1 terms

nonqualified stock option financial

"granted one employee a nonqualified stock option to purchase an aggregate of 60,000 shares"

A nonqualified stock option (NQSO) is a company grant that gives an individual the right to buy shares at a set price but does not meet special tax rules for incentive stock options; when exercised the difference between the market price and the exercise price is treated as ordinary income for the recipient and as a tax-deductible expense for the company. It matters to investors because NQSOs affect an employee’s after-tax proceeds, the company’s reported expenses, and potential share dilution—think of it like a cash bonus that converts into stock but is taxed as regular pay when you take it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (the “Company”) (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted one employee a nonqualified stock option to purchase an aggregate of 60,000 shares of its common stock. The award was approved by the Compensation Committee of the Company’s Board of Directors and was granted pursuant to the Company’s 2026 Inducement Plan, with a grant date of October 1, 2026, as an inducement material to the new employee entering into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option will vest over a four-year period, with 25% of the option vesting on the first anniversary of such employee’s start date, with the remainder of the option vesting in 36 equal monthly installments thereafter, subject to continued employment on each vesting date.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.

Investors and Corporate Contact:

IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares does IN8bio’s October 2026 employee inducement option cover?

The option covers 60,000 shares of IN8bio common stock. It was granted to one new employee on October 1, 2026, under the company’s 2026 Inducement Plan.

What is the vesting schedule for IN8bio’s employee inducement option?

The option vests over four years, subject to continued employment on each vesting date. 25% vests on the first anniversary of the employee’s start date, with the remainder vesting in 36 equal monthly installments thereafter.